Hypoglycaemia Fear, Treatment Adherence, and the Quality of Life in Patients With Type 2 Diabetes and Its Determinants

dc.authorscopusid18039134400en_US
dc.authorscopusid57219433110en_US
dc.authorscopusid57260257500en_US
dc.authorscopusid58915044500en_US
dc.authorwosidAAV-2960-2021en_US
dc.authorwosidAGS-5290-2022en_US
dc.authorwosidABA-0036-2022en_US
dc.authorwosidKGW-4096-2024en_US
dc.contributor.authorYildirim, Dilek
dc.contributor.authorÇiriş Yildiz, Cennet
dc.contributor.authorErgin, Emine
dc.contributor.authorÖzbay, İrem
dc.contributor.authorÖzbay, İrem
dc.date.accessioned2025-02-24T08:24:54Z
dc.date.available2025-02-24T08:24:54Z
dc.date.issued2024en_US
dc.departmentSağlık Bilimleri Fakültesien_US
dc.description.abstractAim: This work aims to evaluate the relationship between the fear of hypoglycaemia,treatment adherence, and the quality of life in patients with type 2 diabetes mellitus(T2DM) and its determinants.Methods: This descriptive and cross-sectional study sample recruited 1060 T2DMoutpatients in a health centre between January and July 2022. The HypoglycemiaFear Survey (HFS), Type 2 DM Treatment Patient Compliance Scale, and the 5-LevelEuroQol 5-Dimension (EQ-5D-5L) were used for data collection.Results: There was a positive correlation between age, duration of T2DM, and thescores obtained from the HFS and its subscales (p < 0.001). There was a positive,moderate correlation between the total HFS score and the TCS (p < 0.001). Therewas a negative correlation between the scores obtained from the HFS and the EQ-5D-5L (p < 0.001). The multiple regression analysis showed that the quality of lifescores of the patients were significantly predicted by hypoglycaemia fear, duration ofT2DM diagnosis, and age. (F = 91.691, p < 0.001). Hypoglycaemia fear, duration ofT2DM diagnosis, and age explained 38.1% of the quality of life of patients.Conclusion: We determined that the increase in hypoglycaemia fear resulted in adecrease in treatment adherence. Besides, hypoglycaemia fear increased withincreasing age and duration of T2DM diagnosis.en_US
dc.identifier.doi10.1111/ijn.13248
dc.identifier.endpage9en_US
dc.identifier.issn1322-7114
dc.identifier.issn1440-172X
dc.identifier.issue2en_US
dc.identifier.orcid0000-0002-6228-0007en_US
dc.identifier.orcid0000-0002-1351-5439en_US
dc.identifier.orcid0000-0001-9419-3146en_US
dc.identifier.orcid0000-0001-5301-0796en_US
dc.identifier.pmid38385845en_US
dc.identifier.scopus2-s2.0-85186408561en_US
dc.identifier.scopusqualityQ1
dc.identifier.startpage1en_US
dc.identifier.urihttps://doi.org/10.1111/ijn.13248
dc.identifier.urihttps://hdl.handle.net/20.500.12436/7329
dc.identifier.volume30en_US
dc.identifier.wos001174158500001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorİrem, Özbay
dc.language.isoen
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Nursing Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHypoglycaemia fearen_US
dc.subjectQuality of lifeen_US
dc.subjectTreatment adherenceen_US
dc.subjectType 2 diabetes mellitusen_US
dc.titleHypoglycaemia Fear, Treatment Adherence, and the Quality of Life in Patients With Type 2 Diabetes and Its Determinantsen_US
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication2ec519b9-c95f-4106-8bc8-cebd78f32a58
relation.isAuthorOfPublication.latestForDiscovery2ec519b9-c95f-4106-8bc8-cebd78f32a58

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
hypoglycaemia-fear-treatment-adherence-and-the-quality-oflife-in-patients-with-type-2-diabetes-and-its-determinants.pdf
Boyut:
270.51 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale dosyası / Article file

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: